Skip to main content
. 2021 Mar 23;4:395. doi: 10.1038/s42003-021-01912-w

Fig. 3. Investigation of the mechanism of action of LRRN4CL.

Fig. 3

a The number of CFDA-positive B16-F0 cells present in the lung (per 2 million lung cells counted) after either 1- or 3-h post-tail vein dosing. The cells were stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB), and then labelled with the fluorescent tracker dye, CFDA. Each symbol represents a mouse, the bars represent mean ± SD, and statistics were performed using a Mann–Whitney t test. b The number of metastatic colonies in the lungs of either wildtype or immunodeficient (NOD-SCID) mice 10 days after being tail vein dosed with B16-F0 cells that have been stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB). Each symbol represents a mouse, the bars represent mean ± SD, two independent experiments were performed (representative data from one experiment is shown) and statistics were performed using a Mann–Whitney t test. c The growth of B16-F0 cells that have been stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB) after subcutaneous administration into the flank of wildtype mice. The data are shown as mean ± SEM with n = 8–9 mice per cell line per experiment. Two independent experiments were performed (representative data from one experiment is shown).